Homocysteine and coronary risk

Area of Science:

• Cardiovascular Medicine
• Nutritional Biochemistry

Background:

• Hyperhomocysteinemia is increasingly recognized as a significant risk factor in coronary artery disease (CAD) pathogenesis.
• Plasma homocysteine levels are influenced by diverse genetic and non-genetic factors.
• The precise mechanisms linking hyperhomocysteinemia to atherosclerosis remain under investigation, though potential adverse effects on vascular endothelium are noted.

Purpose of the Study:

• To explore the role of hyperhomocysteinemia as a risk factor in coronary artery disease.
• To investigate the potential of folic acid in ameliorating the adverse effects of elevated homocysteine.
• To summarize current research on homocysteine-lowering therapy with folic acid for atherosclerotic vascular disease risk.

Main Methods:

• Review of existing literature on homocysteine metabolism and cardiovascular risk.
• Analysis of studies investigating the impact of folic acid on plasma homocysteine levels.
• Examination of epidemiological and clinical trial data related to homocysteine-lowering therapy.

Main Results:

• Hyperhomocysteinemia is associated with an increased risk of atherosclerotic vascular disease.
• Folic acid, even in low doses, demonstrates potential in reducing homocysteine levels.
• Ongoing research aims to confirm the efficacy of folic acid therapy in mitigating cardiovascular events.

Conclusions:

• Hyperhomocysteinemia represents a modifiable risk factor for coronary artery disease.
• Folic acid supplementation shows promise as a therapeutic strategy to lower homocysteine and potentially reduce vascular disease risk.
• Further clinical studies are warranted to establish definitive treatment guidelines.